Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.42 |
| ▸ | ITGB7 | P26010 | 5/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2593341 | 0.92 | ITGA4 (0.48) | ALDH1A1CYP2D6HPGDLMNASMN1; SMN2 | |
| SCHEMBL16700988 | 0.88 | ALDH1A1 (0.45) | ALDH1A1CYP2D6HPGDLMNASMN1; SMN2 | |
| SCHEMBL16700032 | 0.85 | ALDH1A1 (0.43) | ALDH1A1CYP2D6HPGDLMNASMN1; SMN2 | |
| SCHEMBL29664779 | 0.83 | OPRM1 (0.56) | — | |
| SCHEMBL515930 | 0.83 | ITGA4 (0.44) | ALDH1A1CYP2D6HPGDLMNASMN1; SMN2 | |
| SCHEMBL2005769 | 0.83 | OPRM1 (0.56) | — | |
| SCHEMBL25438272 | 0.81 | OPRM1 (0.40) | ALDH1A1LMNAP2RX7VNN1ITGA4 | |
| SCHEMBL19537444 | 0.81 | ALDH1A1 (0.46) | ALDH1A1LMNASMN1; SMN2P2RX7VNN1 | |
| SCHEMBL4825571 | 0.80 | AKR1C1 (0.53) | ALDH1A1LMNAVNN1HSD11B1MEN1 | |
| SCHEMBL23778552 | 0.80 | HIF1A (0.44) | ALDH1A1CYP2D6LMNAITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | MERCK SHARP & DOHME CORP (US) | 2019-10-10 | — | — | US | disclosed |
| EP-3273965-A1 | COMPOSITION AND METHODS FOR TREATING CHRONIC KIDNEY DISEASE | Merck Sharp & Dohme Corp. (US) | 2018-01-31 | — | — | EP | disclosed |
| WO-2016154369-A1 | COMPOSITION AND METHODS FOR TREATING CHRONIC KIDNEY DISEASE | MERCK SHARP & DOHME CORP. (US) | 2016-09-29 | — | — | WO | disclosed |
| EP-1252162-A4 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2003-06-11 | — | — | EP | disclosed |
| EP-1252162-A1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-6472403-B2 | IMIDAZOLIDIN-2-ONE DERIVATIVES; INHIBITING BONE RESORPTION, VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, ARTHRITIS, VIRAL DISEASE, CANCER AND METASTATIC TUMOR GROWTH | MERCK & CO., INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020037889-A1 | Alpha V integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-03-28 | — | — | US | disclosed |
| WO-2001053297-A1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | ITGAM, ITGB1, ITGB2 | ALDH1A1 4365/4885CYP2D6 4873/4885HPGD 2550/4885 |
| US-20020037889-A1 | Alpha V integrin receptor antagonists | ITGAV, ITGB3, ITGA5 | ALDH1A1 2703/4885CYP2D6 4232/4885HPGD 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.